Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week Low – What’s Next?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $18.00 and last traded at $18.05, with a volume of 6643 shares trading hands. The stock had previously closed at $18.29.

Analyst Upgrades and Downgrades

A number of research firms have commented on DNTH. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Guggenheim restated a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $54.33.

Dianthus Therapeutics Trading Down 1.9 %

The stock has a market capitalization of $576.48 million, a P/E ratio of -7.18 and a beta of 1.82. The company has a fifty day simple moving average of $21.94 and a two-hundred day simple moving average of $24.42.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. As a group, analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. FMR LLC increased its holdings in Dianthus Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,439,281 shares of the company’s stock valued at $96,776,000 after purchasing an additional 36,133 shares during the last quarter. Octagon Capital Advisors LP increased its stake in shares of Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after acquiring an additional 363,500 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $32,735,000. Braidwell LP boosted its stake in Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock worth $26,304,000 after acquiring an additional 712,902 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in Dianthus Therapeutics by 13.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock valued at $25,283,000 after purchasing an additional 136,633 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.